Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Digestion ; 84 Suppl 1: 10-6, 2011.
Article in English | MEDLINE | ID: mdl-22156480

ABSTRACT

BACKGROUND AND AIMS: Double-filtration plasmapheresis (DFPP) together with interferon (IFN) administration produces a substantial reduction in the viral load during the early stages of treatment. METHODS: Based on their responses to previous pegylated IFN and ribavirin (PEG-IFN/RBV) therapy, 20 patients were divided into null virological response (NVR; n = 12) and relapse (n = 8) groups. DFPP was used in combination with IFN-ß/RBV with subsequent administration of PEG-IFN-α2a/RBV therapy (DFPP + IFN-ß/RBV then PEG-IFN/RBV). Early viral dynamics was assessed, focusing especially on complete early virological response (cEVR) associated with sustained virological response. Additionally, the interleukin 28B gene, the IFN/RBV resistance-determining region, the IFN sensitivity-determining region and the core regions were analyzed. RESULTS: Rapid virological response was achieved in 0% (0/12) of NVR and in 75% (6/8) of relapse patients, with a significant difference between the two groups (p = 0.001). Similarly, cEVR was achieved in 8% (1/12) of NVR and in 88% (7/8) of relapse patients, with a significant difference between the two groups (p = 0.037). By multivariate logistic regression analysis, interleukin-28B major was a significant determiner of cEVR (odds ratio = 24.19, p = 0.037). CONCLUSION: DFPP + IFN-ß/RBV then PEG-IFN/RBV therapy is indicated more for relapse than for NVR patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/isolation & purification , Hepatitis C, Chronic/therapy , Interferon-alpha/therapeutic use , Interferon-beta/therapeutic use , Plasmapheresis/methods , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Viral Load/drug effects , Adult , Aged , Combined Modality Therapy , Drug Therapy, Combination , Female , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Humans , Interferons , Interleukins/genetics , Male , Middle Aged , RNA, Viral/drug effects , Recombinant Proteins/therapeutic use , Recurrence , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...